Asma Dilawari

870 total citations
29 papers, 256 citations indexed

About

Asma Dilawari is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Asma Dilawari has authored 29 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Asma Dilawari's work include Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (5 papers) and BRCA gene mutations in cancer (4 papers). Asma Dilawari is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (5 papers) and BRCA gene mutations in cancer (4 papers). Asma Dilawari collaborates with scholars based in United States, China and France. Asma Dilawari's co-authors include Christopher Gallagher, Zev M. Nakamura, Jaeil Ahn, Andrew J. Saykin, Richard Pazdur, Brenna C. McDonald, Jeanne S. Mandelblatt, Wanting Zhai, Kathleen Van Dyk and Judith Carroll and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Asma Dilawari

26 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Asma Dilawari United States 10 153 50 45 38 22 29 256
Ahmet Serkan İlgün Türkiye 10 187 1.2× 49 1.0× 44 1.0× 33 0.9× 10 0.5× 27 321
Asim Jamal Shaikh Pakistan 13 139 0.9× 56 1.1× 42 0.9× 50 1.3× 28 1.3× 40 318
Kirsten Sloan United States 4 160 1.0× 32 0.6× 21 0.5× 52 1.4× 18 0.8× 4 268
Elizabeth Cathcart-Rake United States 11 219 1.4× 67 1.3× 54 1.2× 74 1.9× 26 1.2× 56 466
Amir Montazeri United Kingdom 8 195 1.3× 28 0.6× 28 0.6× 18 0.5× 21 1.0× 18 297
Vittorio Gebbia Italy 8 148 1.0× 63 1.3× 39 0.9× 16 0.4× 25 1.1× 46 241
Per-Henrik Zahl Norway 6 159 1.0× 50 1.0× 72 1.6× 24 0.6× 10 0.5× 6 292
Marilot C. T. Batenburg Netherlands 9 187 1.2× 65 1.3× 58 1.3× 24 0.6× 7 0.3× 20 299
David Gómez Spain 11 137 0.9× 44 0.9× 33 0.7× 32 0.8× 29 1.3× 25 278
Elaine Yu United States 10 191 1.2× 102 2.0× 39 0.9× 33 0.9× 27 1.2× 34 314

Countries citing papers authored by Asma Dilawari

Since Specialization
Citations

This map shows the geographic impact of Asma Dilawari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asma Dilawari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asma Dilawari more than expected).

Fields of papers citing papers by Asma Dilawari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asma Dilawari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asma Dilawari. The network helps show where Asma Dilawari may publish in the future.

Co-authorship network of co-authors of Asma Dilawari

This figure shows the co-authorship network connecting the top 25 collaborators of Asma Dilawari. A scholar is included among the top collaborators of Asma Dilawari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asma Dilawari. Asma Dilawari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Srivastava, Geetika, Rupert W. Leong, Abhilasha Nair, et al.. (2024). U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022.. Journal of Clinical Oncology. 42(16_suppl). e13779–e13779. 1 indexed citations
3.
4.
Leong, Rupert W., Jennifer J. Lee, Geetika Srivastava, et al.. (2024). Underrepresentation of Asian Americans, Native Hawaiians, and other Pacific Islanders (AA & NHPI) in cancer clinical trials that led to FDA approvals in 2010-2022.. Journal of Clinical Oncology. 42(16_suppl). 11026–11026. 1 indexed citations
5.
Narayan, Preeti, Asma Dilawari, Christy Osgood, et al.. (2023). US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. Journal of Clinical Oncology. 41(11). 2108–2116. 34 indexed citations
6.
Pohlmann, Paula R., Deena Graham, Yvonne Ottaviano, et al.. (2022). HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Research and Treatment. 196(3). 571–581. 4 indexed citations
7.
Dyk, Kathleen Van, Jaeil Ahn, Xingtao Zhou, et al.. (2022). Associating persistent self-reported cognitive decline with neurocognitive decline in older breast cancer survivors using machine learning: The Thinking and Living with Cancer study. Journal of Geriatric Oncology. 13(8). 1132–1140. 5 indexed citations
8.
Duke, Elizabeth S., Michael Fusco, Asma Dilawari, et al.. (2022). Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development. Cancer Discovery. 12(12). 2739–2746. 6 indexed citations
9.
Rentscher, Kelly E., Xingtao Zhou, Brent J. Small, et al.. (2021). Loneliness and mental health during the COVID‐19 pandemic in older breast cancer survivors and noncancer controls. Cancer. 127(19). 3671–3679. 55 indexed citations
10.
Lynce, Filipa, Matthew Blackburn, Christopher Gallagher, et al.. (2021). Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer. 127(19). 3622–3630. 14 indexed citations
11.
Tiwari, Shruti, et al.. (2020). Abstract P2-10-10: Lower pathologic complete response rate with dual-HER2 blockage and chemotherapy in African Americans and ethnic minorities. Cancer Research. 80(4_Supplement). P2–10. 1 indexed citations
12.
Shaw, James E., et al.. (2019). Innovation, education, and research: A multidisciplinary survivorship care model.. Journal of Clinical Oncology. 37(15_suppl). 10519–10519.
13.
Lynce, Filipa, Ayesha N. Shajahan‐Haq, Christopher Gallagher, et al.. (2018). PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemporary Clinical Trials Communications. 10. 190–192. 8 indexed citations
14.
Dilawari, Asma, et al.. (2018). Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?. Health and Technology. 9(2). 175–184. 11 indexed citations
15.
Sheppard, Vanessa B., Luciane R. Cavalli, Chiranjeev Dash, et al.. (2017). Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer. Clinical Breast Cancer. 17(3). 232–238. 9 indexed citations
16.
Tefera, Eshetu, Pia Herbolsheimer, Raquel Nunes, et al.. (2017). Video intervention increases participation of black breast cancer patients in therapeutic trials. npj Breast Cancer. 3(1). 36–36. 20 indexed citations
17.
Sater, Houssein Abdul, et al.. (2014). Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University’s lung cancer patients. International Journal of General Medicine. 7. 333–333. 6 indexed citations
18.
Sheppard, Vanessa B., et al.. (2014). Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients. Clinical Breast Cancer. 15(2). e83–e92. 8 indexed citations
19.
Said, Rabih, et al.. (2011). Intracranial Rosai-Dorfman. The Neurologist. 17(2). 117–119. 11 indexed citations
20.
Dilawari, Asma. (2009). Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers. ecancermedicalscience. 3. 109–109. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ahmet Serkan İlgün Breakdown of academic impact, for papers by Asim Jamal Shaikh Breakdown of academic impact, for papers by Kirsten Sloan Breakdown of academic impact, for papers by Elizabeth Cathcart-Rake Breakdown of academic impact, for papers by Amir Montazeri Breakdown of academic impact, for papers by Vittorio Gebbia Breakdown of academic impact, for papers by Per-Henrik Zahl Breakdown of academic impact, for papers by Marilot C. T. Batenburg Breakdown of academic impact, for papers by David Gómez Breakdown of academic impact, for papers by Elaine Yu
Rankless by CCL
2026